A new study published in the Journal of the National Cancer Institute has established that institutional volume can significantly influence survival in lung cancer patients receiving chemoradiation.
A new study published in the Journal of the National Cancer Institute has established that institutional volume can significantly influence survival in lung cancer patients receiving chemoradiation. Overall, the 2-year survival rate of patients treated at high-volume centers (HVCs) was over 10% more than that of patients treated at low-volume centers (LVCs).
The retrospective analysis evaluated the outcomes of nearly 500 patients with locally-advanced non-small cell lung cancer (LA-NSCLC) who were enrolled in the NRG Oncology RTOG 0617 trial at 180 institutions. Patients were randomly assigned to receive 60 Gy or 74 Gy radiotherapy (RT), along with carboplatin/paclitaxel, with or without cetuximab. Centers that accrued more than 3 patients in the trial were classified as HVCs. LVCs saw 195 patients participating in the trial (range 1 to 3 patients), while HVCs enrolled 300 (range 4 to 18).
The analysis found that patients treated at HVCs had significantly longer overall and progression-free survival (OS and PFS, respectively). Median OS at HVCs was 26.2 months, compared with 19.8 months at LVCs (HR, 0.70; 95% CI, 0.56-0.88; P = .002). Median PFS at HVCs was 11.4 months while at LVCs it was 9.7 months (HR, 0.80; 95% CI, 0.65-0.99, P = .04). The authors report in their paper that patients at HVCs had much lower adverse events (AEs), most likely because they had a lower esophageal dose as well as a lower heart dose, compared with patients at LVCs. Grade 5 AEs (5.3% vs 9.2%, P = .09) and RT termination because of AEs (1.3% vs 4.1%, P = .07) were less common among patients treated at HVCs, they write.
This is significant, according to lead author Bree R. Eaton, MD, a radiation oncologist at the Winship Cancer Institute at Emory University. “It’s hard to say conclusively but the underlying hypothesis and belief is that at large volume centers, where physicians and care team are specialized in treating that specific type of malignancy, particularly in instances where treatment is life-saving or the risk for severe toxicity is high, that outcomes are better at high volume centers, as opposed to small community centers where the people there treat a variety of things,” Eaton told Reuters Health. “Radiation as a technology has advanced and is a lot more complex than it used to be. In general there’s a lot of nuances and subjectivity,” she added.
Commenting on the study, Henry Soo-Min Park, MD, MPH, of Yale University School of Medicine told Reuters that the fact that about 25% of the patients at HVCs survived for at least 5 years is a significant outcome. “This disease is difficult to control but is potentially curable in some patients following aggressive treatment,” Park said.
Reference
Eaton BR, Pugh SL, Bradley JD, et al. Institutional enrollment and survival among NSCLC patients receiving chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617. J Natl Cancer Inst. 2016;108(9). pii: djw034. doi: 10.1093/jnci/djw034.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More